Hemab Therapeutics Holdings, Inc. Common Stock (COAG) vs Ultragenyx Pharmaceutical Inc. (RARE)

A side-by-side comparison of Hemab Therapeutics Holdings, Inc. Common Stock and Ultragenyx Pharmaceutical Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Hemab Therapeutics Holdings, Inc. Common Stock logo
COAG
Hemab Therapeutics Holdings, Inc. Common Stock
$1.33B
$28.37HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Ultragenyx Pharmaceutical Inc. logo
RARE
Ultragenyx Pharmaceutical Inc.
$1.42B
$14.46HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — COAG vs RARE

growth of $100 · dividends reinvested · last 1y
COAG -10.0% (-10.0%/yr)RARE -41.5% (-41.5%/yr)COAG compounded faster over this window
50100150Start $100$90$59
COAG RARE

COAG vs RARE: by the numbers

  • •RARE is the larger company ($1.42B vs $1.33B market cap).
  • •Both run net losses; COAG's is the smaller (0.00% vs -81.79% net margin).

Metrics side by side

Valuation

MetricCOAGRARE
P/S ratioN/A1.99
P/B ratio2.92N/A

Profitability

MetricCOAGRARE
Gross margin0.00%83.12%
Operating margin0.00%-73.77%
Net margin0.00%-81.79%
ROIC-38.09%-53.48%

Growth (annualized)

MetricCOAGRARE
Revenue CAGR (5Y)N/A14.81%
Total return CAGR (5Y)N/A-30.14%

Go deeper

Full COAG analysisFull RARE analysisInteractive comparison tool

Dig into the metrics

Hemab Therapeutics Holdings, Inc. Common Stock ROEUltragenyx Pharmaceutical ROEHemab Therapeutics Holdings, Inc. Common Stock operating marginUltragenyx Pharmaceutical operating marginHemab Therapeutics Holdings, Inc. Common Stock revenue growthUltragenyx Pharmaceutical revenue growthHemab Therapeutics Holdings, Inc. Common Stock free cash flowUltragenyx Pharmaceutical free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.